R&D setbacks are not palatable at premium valuations
08/09/26 -"The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term outlook. While a healthy longer-term ..."
Pages
69
Language
English
Published on
08/09/26
You may also be interested by these reports :
09/09/26
The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because ...
08/09/26
The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term ...
04/09/26
While we have tweaked our earnings estimates slightly higher, the decline in our target price is owing to the removal of a peer which was skewing the ...
04/09/26
We have tweaked our earnings estimates lower and considering the recent late-stage setbacks for cardiovascular (Wainua) and oncology (Volrustomig) ...